As Kenvue Inc. KVUE prepares to unveil its third-quarter fiscal 2026 results on Oct. 30, before market open, investors are eager to see whether the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.3% growth from the prior year. Meanwhile, the consensus mark for earnings has remained unchanged at 28 cents per share in the past seven days and implies flat year-over-year. KVUE has an average trailing four-quarter earnings surprise of 10.5%.
Key Factors to Observe for KVUE's Q3 Earnings
Kenvue's performance is likely to have benefited from improving organic sales trends, brand-building initiatives and product innovation in the third quarter of 2026. The company has been witnessing encouraging momentum across its consumer health portfolio, supported by stronger commercial execution and expanding e-commerce capabilities. Continued investments in core brands, improved market penetration and favorable pricing across select categories are likely to have supported quarterly performance.
Kenvue's Self Care segment is likely to have gained from improving demand for allergy, digestive health and pain relief products. Strong execution behind Zyrtec and Pepcid, along with improving consumption trends for Tylenol, might have supported sales. The company's smoking cessation portfolio, particularly Nicorette, has also been witnessing healthy momentum across international markets. However, softer category demand and uneven consumer purchasing patterns might have limited volume growth.
On the profitability front, Kenvue's ongoing supply-chain optimization and cost-saving initiatives under Our Vue Forward and its 2026 restructuring program are likely to have supported operating efficiencies. Improved productivity and disciplined cost management might have provided some relief.
Nevertheless, inflationary pressures, tariffs, unfavorable transactional currency movements and increased brand-support spending are likely to have weighed on margins. Heightened competition and cautious consumer spending might also have affected the quarter's overall performance.
What the Zacks Model Says About KVUE
Our proven model does not conclusively predict an earnings beat for KVUE this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
KVUE has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are three companies you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:
BJ’s Wholesale Club Holdings, Inc. BJ has an Earnings ESP of +2.54% and currently carries a Zacks Rank of 2. The Zacks Consensus Estimate for third-quarter fiscal 2026 earnings per share is pegged at 1.22 cents, implying 5.2% year-over-year growth. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.6 billion, which indicates an increase of 6.2% from the figure reported in the prior-year quarter. BJ has a trailing four-quarter earnings surprise of 11.1%, on average.
Colgate-Palmolive Company CL has an Earnings ESP of +0.01% and currently carries a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter fiscal 2025 earnings per share is pegged at 92 cents, implying 1.1% year-over-year growth.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.3 billion, which indicates an increase of 3.9% from the figure reported in the prior-year quarter. CL has a trailing four-quarter earnings surprise of 3.2%, on average.
Church & Dwight Co., Inc. CHD currently has an Earnings ESP of +0.06% and a Zacks Rank of 3. The Zacks Consensus Estimate for third-quarter fiscal 2027 earnings per share is pegged at 90 cents, implying an 11% year-over-year increase.
The Zacks Consensus Estimate for quarterly revenues is pegged at $1.6 billion, which indicates a decline of 0.2% from the figure reported in the prior-year quarter. CHD has a trailing four-quarter earnings surprise of 1%, on average.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kenvue Inc. (KVUE): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
BJ's Wholesale Club Holdings, Inc. (BJ): Free Stock Analysis Report
Church & Dwight Co., Inc. (CHD): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).